In this regard, neutralizing antibodies against IL-17A and IL-17RA, which have been tested safe and effective for the treatment of autoimmunity in humans [48], may be tested as adjuvant therapies that accompany current cancer immunotherapies. Here, IL17RA is linked to cancer.